# HELPS Study - A Study of Peginterferon Alfa-2a (Pegasys) in Patients With Chronic Hepatitis C (CHC) and End-Stage Renal Disease (ESRD)

> **NCT02806505** · PHASE3 · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 81 (actual)

## Conditions studied

- Hepatitis C, Chronic

## Interventions

- **DRUG:** Peginterferon alfa-2a

## Key facts

- **NCT ID:** NCT02806505
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-06
- **Primary completion:** 2007-08
- **Final completion:** 2007-08
- **Target enrollment:** 81 (ACTUAL)
- **Last updated:** 2016-10-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02806505

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02806505, "HELPS Study - A Study of Peginterferon Alfa-2a (Pegasys) in Patients With Chronic Hepatitis C (CHC) and End-Stage Renal Disease (ESRD)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02806505. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*